RU2016152226A - Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения - Google Patents

Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения Download PDF

Info

Publication number
RU2016152226A
RU2016152226A RU2016152226A RU2016152226A RU2016152226A RU 2016152226 A RU2016152226 A RU 2016152226A RU 2016152226 A RU2016152226 A RU 2016152226A RU 2016152226 A RU2016152226 A RU 2016152226A RU 2016152226 A RU2016152226 A RU 2016152226A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
prostaglandin
inhibitor
specified
urination
Prior art date
Application number
RU2016152226A
Other languages
English (en)
Russian (ru)
Other versions
RU2016152226A3 (enExample
Inventor
Дэвид А. ДИЛЛ
Фрэнк Дж. РАУШЕР
Original Assignee
УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of RU2016152226A3 publication Critical patent/RU2016152226A3/ru
Publication of RU2016152226A publication Critical patent/RU2016152226A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016152226A 2014-06-06 2014-06-06 Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения RU2016152226A (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/041378 WO2015187183A1 (en) 2014-06-06 2014-06-06 Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Publications (2)

Publication Number Publication Date
RU2016152226A3 RU2016152226A3 (enExample) 2018-07-09
RU2016152226A true RU2016152226A (ru) 2018-07-09

Family

ID=54767122

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016152226A RU2016152226A (ru) 2014-06-06 2014-06-06 Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения

Country Status (9)

Country Link
EP (1) EP3151834A4 (enExample)
JP (1) JP2017516832A (enExample)
KR (1) KR20170010440A (enExample)
CN (1) CN106714805A (enExample)
AU (1) AU2014396189A1 (enExample)
MX (1) MX2016016039A (enExample)
RU (1) RU2016152226A (enExample)
SG (1) SG11201610383YA (enExample)
WO (1) WO2015187183A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
WO2017106032A1 (en) * 2015-12-18 2017-06-22 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
JP2019031556A (ja) * 2018-10-31 2019-02-28 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法
WO2021154974A1 (en) * 2020-01-30 2021-08-05 The Regents Of The University Of California Screening for inhibitors of prostaglandin e synthase 3 useful for treatment of prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
EP1447096A1 (en) * 2001-11-19 2004-08-18 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
JP2005526040A (ja) * 2002-02-19 2005-09-02 ファルマシア・コーポレーション 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
KR20190049928A (ko) * 2012-01-04 2019-05-09 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
MX2014008283A (es) * 2012-01-04 2015-03-03 Wellesley Pharmaceutical Llc Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
WO2013142197A1 (en) * 2012-03-19 2013-09-26 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
JP2017516832A (ja) 2017-06-22
CN106714805A (zh) 2017-05-24
WO2015187183A1 (en) 2015-12-10
KR20170010440A (ko) 2017-01-31
SG11201610383YA (en) 2017-02-27
EP3151834A1 (en) 2017-04-12
AU2014396189A1 (en) 2016-12-22
RU2016152226A3 (enExample) 2018-07-09
EP3151834A4 (en) 2018-01-03
MX2016016039A (es) 2017-08-24

Similar Documents

Publication Publication Date Title
RU2016152226A (ru) Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения
RU2014142066A (ru) Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
WO2012079092A3 (en) Testosterone undecanoate compositions
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
RU2013121788A (ru) Ингибиторы репликации вич
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
JP2009541443A5 (enExample)
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
FI3838271T3 (fi) Kohonneiden eosinofiilien ja/tai basofiilien pitoisuuksien hoito
JP2015510928A5 (enExample)
RU2014131238A (ru) Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения
ECSP11011453A (es) Tratamiento de trastornos cognitivos con determinados receptores de ácido nicotínico alfa-7 en combinación con inhibidores de acetilcolinesterasa
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
HRP20171743T1 (hr) Sastavi i postupci za savladavanje otpornosti na tramadol
MX351059B (es) Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
AR078951A1 (es) Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
AR073435A1 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
JP2017516832A5 (enExample)
MX2014002480A (es) Uso del compuesto organico para el tratamiento del sindrome de noonan.
RU2015106672A (ru) Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения
JP2015522659A5 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200116